<DOC>
	<DOCNO>NCT01014416</DOCNO>
	<brief_summary>To investigate safety , tolerance , pharmacokinetics pharmacodynamics tolvaptan 15 , 30 60 mg single oral administration healthy Korean male subject .</brief_summary>
	<brief_title>Pharmacokinetics/Pharmacodynamics ( PK/PD ) Characteristics Tolvaptan Tablet Korean Healthy Male</brief_title>
	<detailed_description />
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1 . Healthy Korean male subject 20 45 year age , inclusive . 2 . Body Mass Index ( BMI ) 20 26 kg/m2 , body , weight ≥ 50kg BMI = weight ( kg ) /height2 ( ) 3 . Informed consent subject 1 . Clinically significant abnormality respiratory , cardiovascular , hepatic , neurologic , endocrine , hematologic , urinary , psychiatric . 2 . History gastrointestinal disease surgery affect intestinal absorption study drug . 3 . History significant drug allergy hypersensitivity . 4 . AST ALT &gt; 1.25 time upper normal limit screen clinical laboratory test 5 . Supine blood pressure rest ≥ 3 minute , high 140/90 mmHg low 100/50 mmHg , Supine pulse , rest ≥ 3 minute , outside range 40 90 beats/minute . 6 . Subjects history drug abuse alcohol addiction 7 . Subjects use prescription drug herbal medication within 2 week prior first dose study drug , overthecounter vitamin supplement within 1 week prior first dose ( However , investigator judge subject , take medication period , eligible trial condition satisfy ) 8 . The investigator judge subject eligible study review clinical laboratory result reason .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Healthy Korean male</keyword>
</DOC>